Anti-Apolipoprotein CIII antibody [EPR19732-13] - BSA and Azide free (Detector)

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Apolipoprotein CIII also known as Apo C-III or ApoC3 is an apolipoprotein with a molecular mass of approximately 8.8 kDa. It is synthesized in the liver and intestine and circulates in the bloodstream primarily as part of very low-density lipoproteins (VLDL) and high-density lipoproteins (HDL). Its main role involves the regulation of lipid metabolism particularly in relation to triglyceride-rich particles. Apo C-III serves as an inhibitor of lipoprotein lipase an enzyme essential for the hydrolysis of triglycerides into free fatty acids.

Biological function summary

Apolipoprotein CIII plays a pivotal role in lipid and lipoprotein metabolism. It is not part of a large protein complex but interacts with lipoproteins as a modulatory protein. Apo C-III affects triglyceride metabolism by delaying the clearance of VLDL and enhancing hepatic triglyceride secretion. Additionally it modulates the uptake of lipoprotein remnants by liver receptors thereby influencing the plasma levels of triglycerides and cholesterol.

Pathways

Apolipoprotein CIII is involved in the regulation of lipid metabolic pathways. It plays a role in the lipoprotein assembly pathway and the triglyceride biosynthetic process. This protein impacts the interaction between lipoprotein lipase and its substrates hindering enzyme activity which leads to elevated plasma triglyceride levels. It relates closely to other apolipoproteins such as apolipoprotein E which also participates in lipid transport and metabolism although with distinct functions and regulatory mechanisms.

Associated diseases and disorders

Apolipoprotein CIII is implicated in conditions like hypertriglyceridemia and cardiovascular disease. Elevated levels of Apo C-III contribute to high triglyceride levels promoting atherosclerosis development due to the retention of triglyceride-rich lipoproteins in the bloodstream. This association links it to cardiovascular disease risk where its role contrasts with proteins like apolipoprotein AI which is mainly involved in protective effects via HDL metabolism. Understanding the modulation of Apo C-III levels offers potential therapeutic avenues for managing these lipid-related disorders.